Global Chronic Obstructive Pulmonary Disease (COPD) Market Analysis 2025–2033

Chronic Obstructive Pulmonary Disease Market Size

The Chronic Obstructive Pulmonary Disease (COPD) Market valued at USD 13.18 billion in 2024 and is expected to reach USD 16.61 billion by 2033 with a CAGR of 2.60% during the forecast period of 2025 to 2033. The market growth is triggered by the mounting incidence of COPD due to increasing air pollution, smoking tendencies, and age groups. Innovation in treatment approaches, such as bronchodilators, combination therapy, and biologics, also add to market growth

The report Chronic Obstructive Pulmonary Disease (COPD) Market Global Forecast covers by Types (Chronic Bronchitis, Emphysema) Treatment Types (Drugs, Oxygen Therapy, Surgery, Others) Distribution Channels (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) Countries and Company Analysis, 2025-2033.

Chronic Obstructive Pulmonary Disease Market Overview

Chronic Obstructive Pulmonary Disease (COPD) refers to a progressive lung disorder that results in breathing problems due to the obstruction of airflow. It comprises diseases such as emphysema and chronic bronchitis, usually brought about by smoking, long-term exposure to air pollution, or environmental hazards. COPD results in symptoms of shortness of breath, chronic cough, and excess mucus, which severely impact an individual's quality of life.

Treatment for COPD attempts to control symptoms, delay disease progression, and enhance lung function. Therapies include bronchodilators, corticosteroids, oxygen, and pulmonary rehabilitation. Technological improvement in inhalers and biologic drugs has improved treatment. With growing international awareness of respiratory conditions, COPD diagnosis and management have become a priority. Increased cases due to pollution and aging populations have turned COPD into a serious healthcare issue, prompting governments and healthcare providers to invest in improved treatment availability and research, thus making it a priority in the global respiratory care market.

Growth Drivers in the Chronic Obstructive Pulmonary Disease Market

Increased Prevalence of COPD

Increased prevalence of COPD is a primary driver of market growth. Reasons like escalating air pollution, increasing elderly population, and higher smoking prevalence fuel the increase in COPD incidence globally. One of the biggest causes of mortality worldwide, the WHO says that COPD accounts for it. Market growth will be spurred on by increasing the number of treated cases, along with rising numbers of diagnosed ones, as growing demand for the effective treatment will be triggered. Chronic obstructive pulmonary disease (COPD) is the fourth most common cause of death globally, with 3.5 million deaths in 2021, which represents about 5% of all deaths worldwide. Tobacco smoking is responsible for more than 70% of COPD cases in high-income nations. In low- and middle-income countries (LMIC), tobacco smoking accounts for 30-40% of COPD cases, with household air pollution also being a major risk factor.

Advancements in COPD Treatment Options

The ongoing development of treatment strategies, such as combination inhalers, biologic treatments, and non-invasive ventilation, is strongly driving the COPD market. Pharmaceutical firms are putting money into research and development to develop more potent and longer-lasting treatments. New drug delivery systems, like smart inhalers, are enhancing patient compliance and outcomes, further driving market growth. Oct 2024, Ohtuvayre is a dual selective inhibitor of phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4), standing out in COPD by dilating airways and lessening inflammation.

Government and Healthcare Initiatives

Governments and healthcare systems across the globe are aggressively working towards raising awareness, enhancing early diagnosis, and promoting access to COPD treatment. Public health campaigns, better reimbursement policies, and investment in respiratory care facilities are supporting market growth. Programs promoting smoking cessation and air quality improvements are also contributing to reducing COPD cases while driving demand for advanced therapeutic solutions. AstraZeneca Pharma India has received approval from the DCGI to import and market Breztri Aerosphere, an inhalation therapy for the treatment of COPD. The product, which combines three active ingredients, is set to launch in India in January 2025.

Challenges in the Chronic Obstructive Pulmonary Disease Market

High Treatment Cost of COPD

High treatment cost of COPD medications, oxygen therapy, and advanced surgeries is a major hindrance to market expansion. Most patients, especially in emerging markets, cannot afford the proper treatment. Inadequate healthcare coverage and high out-of-pocket costs limit access to needed drugs, stunting the market's growth.

Lack of Early Diagnosis and Awareness

Although COPD is a significant health issue, it is underdiagnosed because patients and healthcare professionals lack awareness. Most patients do not visit doctors until the condition has advanced extensively. Lack of standardized screening programs and misperceptions regarding symptoms cause delays in treatment, which results in poorer patient outcomes and restricts market growth.

Emphysema Chronic Obstructive Pulmonary Disease Market

Emphysema, a type of COPD, causes damage to the lung's alveoli, resulting in diminished oxygen exchange. The emphysema market is propelled by rising instances because of smoking and air pollution. Therapies like inhaled bronchodilators, corticosteroids, and oxygen therapy are being used extensively. Lung volume reduction operations and minimal invasive techniques like endobronchial valves are becoming popular as effective therapeutic options, boosting market growth even further.

Chronic Obstructive Pulmonary Disease Drugs Market

The COPD drug market is growing because of increased demand for bronchodilators, corticosteroids, and combination inhalers. Pharmaceutical firms are manufacturing advanced drugs that are more effective and have fewer side effects. The advent of biologics and targeted therapies is changing the scenario of COPD treatment, enhancing patient outcomes. More government approvals for new drugs and enhanced reimbursement policies are also contributing to market growth.

Chronic Obstructive Pulmonary Disease Surgery Market

Operations like lung volume reduction surgery (LVRS) and lung transplantation are vital for extreme cases of COPD. Advances in minimally invasive surgical procedures have enhanced patient outcomes and lowered recovery times. The proliferation of specialized respiratory care centers and the accessibility of sophisticated surgical instruments are fueling the growth of the COPD surgery market.

Chronic Obstructive Pulmonary Disease Hospital Market

Hospitals are essential in the treatment of COPD, offering diagnosis, medication management, oxygen therapy, and surgery. Hospital-based COPD care is increasingly needed as cases become more severe upon hospitalization. Enhanced healthcare infrastructure, government subsidies, and enhanced diagnostic facilities in hospitals are propelling this market segment's growth.

Chronic Obstructive Pulmonary Disease Online Pharmacies Market

The growth of web pharmacies is revolutionizing the COPD market with easy access to drugs. Patients can conveniently buy inhalers, oxygen concentrators, and other COPD medicines online, allowing for greater compliance with prescribed therapy. Affordable pricing, doorstep delivery, and telemedicine facilities add to the ease of COPD drug access, driving the market forward.

USA COPD Market

The United States is burdened with a high COPD prevalence, mainly attributable to high prevalence rates of smoking and air pollution. The availability of sophisticated healthcare infrastructure, large insurance coverage, and research activities for new treatment modalities are promoting market growth. The rise in the usage of biologics and smart inhalers is also boosting demand in the U.S. COPD market. Sept 2024, The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as add-on maintenance treatment for adults with inadequately controlled chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype.

France COPD Market

France possesses a well-established healthcare system, and its COPD market is influenced by increasing awareness campaigns and smoking cessation programs. Government-funded respiratory health programs and growing investments in new drug forms are favorably influencing market growth. France also has an increasing need for sophisticated inhalers and oxygen therapy equipment, improving its COPD treatment scenario. July 2024, The European Medicines Agency (EMA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) with increased blood eosinophils.

India COPD Market

India's COPD market is growing with increasing levels of pollution, exposure to biomass fuel, and smoking. Limited healthcare access in rural areas poses challenges, but government initiatives to improve COPD awareness and early diagnosis are helping. The availability of affordable generic drugs and increasing medical infrastructure development are supporting the market’s growth. November 23, 2023: Indian pharma major Lupin Limited (Lupin) has declared that it has launched the world's first fixed-dose triple combination drug (FDC) branded as Vilfuro-G® for effective COPD management in India.

Saudi Arabia COPD Market

The COPD market in Saudi Arabia is driven by high smoking prevalence and growing environmental pollution. The government is making investments in healthcare facilities and boosting respiratory health initiatives. The increasing use of telemedicine and online pharmacies is enhancing access to COPD medicines. Moreover, innovation in inhaler technology and biologic therapies is augmenting the treatment landscape in the region. Sept 2024, EVA Pharma reports first-time implementation of its strategies to cater to Asthma and COPD patients in Saudi Arabia. This is a major step towards fulfilling the local needs of patients in the region and strengthens EVA Pharma's commitment to delivering sustainable and affordable healthcare solutions.

Chronic Obstructive Pulmonary Disease (COPD) Market Segmentation

Types

• Chronic Bronchitis
• Emphysema
•  

Treatment Types

• Drugs
• Oxygen Therapy
• Surgery
• Others

Distribution Channels

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Regional Market Insights

North America

• United States
• Canada

Europe

• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• Netherlands
• Turkey

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Thailand
• Malaysia
• Indonesia
• New Zealand

Latin America

• Brazil
• Mexico
• Argentina

Middle East & Africa

• South Africa
• Saudi Arabia
• UAE

All the Key players have been covered from 4 Viewpoints:

• Overviews
• Key Person
• Recent Developments
• Product Portfolio     
• Revenue

Leading Companies and Competitive Landscape

• AstraZeneca
• Pfizer, Inc.
• GlaxoSmithKline plc.
• Novartis AG
• Astellas Pharma Inc.
• Abbott Laboratories
• Boehringer Ingelheim International GmbH
• Almirall

Report Details:

Customization Services available

• Analysis of Market Size and Its Segments
• More Company Profiles (Upto 10 without any additional cost):
• Additional Countries (Other than mentioned Countries):
• Region/Country Specific Reports:
• Market Entry Strategy:
• Region-Specific Market Dynamics:
• Regional Market Share Analysis:
• Trade Analysis:
• Production Insights:
• Others Customized Requests:

For more information contact our analysts.

Need More Assistance?

• Talk to our analysts to get more precious information on the current market trends.
• Include more countries and segments and customize the report based on the final requirement.
• Get a competitive advantage in your industry by knowing the report findings and making a positive impact on your revenues and operations.
• Our analysts are always ready to provide more help and pertinent information if you need any additional assistance.